OVID
Ovid Therapeutics Inc

6,119
Mkt Cap
$216.11M
Volume
1.39M
52W High
$2.01
52W Low
$0.2425
PE Ratio
-3.25
OVID Fundamentals
Price
$1.70
Prev Close
$1.66
Open
$1.61
50D MA
$1.61
Beta
1.18
Avg. Volume
1.15M
EPS (Annual)
-$0.3728
P/B
2.64
Rev/Employee
$24,608.70
$27.88
Loading...
Loading...
News
all
press releases
Ovid Therapeutics (OVID) to Release Quarterly Earnings on Tuesday
Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...
MarketBeat·24h ago
News Placeholder
More News
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts
Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have earned a consensus recommendation of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·3d ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% Higher - Should You Buy?
Ovid Therapeutics (NASDAQ:OVID) Trading 7.3% Higher - Time to Buy...
MarketBeat·6d ago
News Placeholder
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -700.58% and -45.96%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
Ovid Therapeutics $OVID Position Cut by TLS Advisors LLC
TLS Advisors LLC lowered its holdings in shares of Ovid Therapeutics (NASDAQ:OVID - Free Report) by 97.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·1mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen lowered Ovid Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold"
Wall Street Zen upgraded Ovid Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
FY2025 Earnings Forecast for OVID Issued By Lifesci Capital
Ovid Therapeutics (NASDAQ:OVID - Free Report) - Equities researchers at Lifesci Capital issued their FY2025 earnings estimates for Ovid Therapeutics in a research report issued on Monday, December...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital
Lifesci Capital assumed coverage on shares of Ovid Therapeutics in a research report on Monday. They set an "outperform" rating and a $4.00 price objective for the company...
MarketBeat·2mo ago
News Placeholder
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $2.00 price objective on shares of Ovid Therapeutics in a research report on Monday...
MarketBeat·2mo ago
<
1
2
...
>

Latest OVID News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.